Medline Faces Securities Fraud Probe Following FDA Warning and Stock Slump

The investigation centers on allegations that Medline failed to provide accurate disclosures concerning its operational compliance. Tensions surfaced on June 2, 2026, when the FDA issued a warning letter citing significant violations of Current Good Manufacturing Practice regulations. Regulators noted that the company failed to adequately investigate batch discrepancies, causing Medline shares to drop 7% that day.

Financial instability deepened during the company’s second-quarter earnings call on August 5. Management admitted that remediation efforts required to address the FDA’s findings resulted in substantial earnings losses. This disclosure prompted a further 13% slide in the company's valuation. Bleichmar Fonti & Auld LLP is currently evaluating potential legal recourse for investors who suffered losses during this period, operating on a contingency fee basis.